Skip to content

Study Details

An open-label, multicenter study to evaluate pharmacokinetics, safety and tolerability up to 6 years of intravenous secukinumab infusions in pediatric participants with Juvenile Psoriatic Arthritis

(IRB#: IRB_00190482)

The purpose of this study is to find out how secukinumab behaves in the body, and how safe and well tolerated it is, when it is given multiple times through a vein to children with juvenile psoriatic arthritis.

I AM INTERESTED

  • All genders
  • All Ages
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: All Ages

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • 1. Boys or girls who are 2 to 17 years old.
  • 2. The child has been diagnosed with juvenile psoriatic arthritis at least 6 months ago.
  • 3. The child currently has active arthritis, meaning 3 or more joints are affected. An affected joint may be swollen, or painful and difficult to move.
  • 4. The child has tried at least one nonsteroidal antiinflammatory drug (NSAID) (such as ibuprofen or naproxen) for at least one month, and it didn't work well enough, or the child could not tolerate the side effects.
  • 5. The child has tried at least one diseasemodifying antirheumatic drug (DMARD) for at least two months, and it didn't work well enough, or caused side effects not tolerated by the child.

Exclusion Criteria

  • 1. The child weighs less than 22 pounds at the screening visit.
  • 2. The child has taken an investigational (experimental) medication within the last 4 weeks, or within a time period where the effects of that drug may still be present.
  • 3. The child has had a serious allergic reaction to Secukinumab,any ingredient in the study drug, or medications similar to this study drug.
  • 4. The child currently has active inflammatory bowel disease (such as Crohns disease or ulcerative colitis) or active eye inflammation (uveitis).
  • 5. The child is currently taking arthritismodifying medications other than methotrexate (MTX).

Will I be paid for my time?

Yes

For more information contact:

Suzy Richins

suzy.richins@hsc.utah.edu

  801-585-5067

IRB#: IRB_00190482

PI: PETER CHIRASEVEENUPRAPUND

Department: PEDIATRIC IMMUNOLOGY/RHEUMATOL

Approval Date: 2026-05-27 06:00:00

Specialties: Rheumatology

Last Updated: 6/8/23